{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-005439","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.248038+00:00","generated_at":"2026-05-30T22:54:38.997082+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioCryst begins Phase 1 trial of BCX17725 (KLK5 inhibitor) for Netherton syndrome","bullets":["First participant enrolled in Phase 1 trial of BCX17725, a KLK5 inhibitor for Netherton syndrome.","Trial to evaluate safety, tolerability, PK and immunogenicity in healthy adults and Netherton patients.","Initial data from the trial expected by end of 2025; no approved treatments currently exist for the disease.","BCX17725 is BioCryst's first protein therapeutic to advance to the clinic.","Netherton syndrome is an ultra-rare, life-threatening genetic disorder affecting skin, hair, and immune system."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-005439","json":"https://secwatch.observer/filing/0001171843-24-005439.json","markdown":"https://secwatch.observer/filing/0001171843-24-005439.md","text":"https://secwatch.observer/filing/0001171843-24-005439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324005439/0001171843-24-005439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324005439/f8k_100224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:54:38.997082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}